RxDoctor Payments Data

Lori Evans, PA

Physician Assistant · Winter Park, FLNPI 1659453439

Payments from drug & device makers

$22,261in general payments, 2019–2025

Across 213 payments — averaging $104.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$19K
  • AbbVie$790
  • Johnson & Johnson$303
  • Takeda Pharmaceuticals U.S.A., Inc.$276
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$269
  • Gilead$167
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$3,78017%
  • Speaking & faculty fees$11,74553%
  • Travel & lodging$2,34111%
  • Food & beverage$4,26019%
  • Education$1351%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,261 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$24,179
Medicare patients
129
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom39$153,505
MounjaroTirzepatide105$106,669
OzempicSemaglutide37$34,323
Topiramate31$149
Rosuvastatin Calcium12$82
Metformin Hcl ErMetformin Hcl14$40
Metformin Hcl15$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$19,416$153,50539 claims
Lilly USA, LLCMounjaro$26$106,669105 claims
Novo NordiskOzempic$32$34,32337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →